Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 19.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)^TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Thursday, January 26, 2023. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 19.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives

Despite tremendous progress in the field, cancer continues to be a global public health challenge, accounting for 1,670 deaths per day around the world. In the United States (U.S.) alone, it is predicted that 608,570 people will die from some form of cancer in 2021, making it the second most common cause of death after heart disease.  For many of the most common cancers in the U.S., incidence has been declining for more than a decade.  However, incidence of other forms of cancer—including breast, renal pancreatic, endometrial, liver, and melanoma—has been on the rise. In Japan, there were 420,124 deaths from cancer in 2020; colorectal, lung, stomach, prostate, and breast cancer were the most common forms of cancer diagnosed.  One of the challenges we face is that cancer comprises more than 200 different diseases. This broad-based meeting eliminates geographic barriers by bringing together outstanding researchers, practicing oncologists, and clinical investigators from North America, Japan, and the greater Pacific Rim in Maui as a central location to facilitate the direct, personal interactions that are required to move the field of cancer research and treatment forward.

With the accelerating pace of discoveries in the basic, translational, and clinical sciences, due in large part to the advent of new technologies, cancer researchers are making rapid progress that is having significant patient benefit. There is a need to ensure that the latest advances are being disseminated globally. This broad-based meeting eliminates geographic barriers by bringing together outstanding researchers from North America, Japan, and the greater Pacific Rim in Maui as a central location to facilitate the direct, personal interactions that are required to move the field of cancer research and treatment forward. There is a need for these types of interactions between basic researchers, physicians, and clinician-scientists at all career levels so that they may obtain, synthesize, and integrate the most cutting-edge research into their own laboratories and practices. This exposure to information and best practices in different countries may aid in the development and implementation of best practices (such as the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer) in other regions. Further, facilitating the interface between physicians and scientists on an international scale will increase knowledge of the epidemiological implications of cancer incidence and the contributions of laboratory research to drug development as well as patient care.

This broad-based meeting eliminates geographic barriers by bringing together outstanding researchers from North America, Japan, and the greater Pacific Rim in Maui as a central location to facilitate the direct, personal interactions that are required to move the field of cancer research and treatment forward. The information shared will arm practicing oncologists and clinical investigators with knowledge across several emerging areas that have the potential to positively impact patient outcomes.

After participating in this CME activity, physicians should be able to:

1. Identify model systems, technological advances, and tools to accelerate progress in cancer research, improve early detection, and early intervention, with the ultimate goal of extending patients’ lives and improving their quality of life.
2. Evaluate the impact of tumor evolution in developing resistance to therapy and exploit tumor heterogeneity to design improved strategies for cancer prevention, interception, and treatment.
3. Assess immunological, metabolic, and tumor microenvironmental contributions towards cancer initiation, progression, and treatment response.
4. Identify factors, including genetic and environmental factors, that impact the early detection, diagnosis, treatment, and prevention of various forms of cancers in patients from diverse populations.
5. Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs.
6. Assess the mechanisms for drug resistance and identify emerging areas for targeted interventions.
7. Develop collaborations amongst physicians, researchers, and clinician-scientists to advance the cause of treating and preventing cancer worldwide.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with ineligible companies whose primary business is producing , marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters:

Lead Supporter

AbbVie

This activity is also supported by Professional Educational Grants which will be disclosed at the activity.

Questions about CME?

Please read our frequently asked questions. If you still have questions, please contact the Office of CME at (215) 440-9300 or [email protected].